CURRICULUM VITAE

BRIAN DAUNTER

B.Sc. M.Sc. PhD.

Unit 9/14 Vista Street

Surfers Paradise
Qld. 4217

Phone. (07) 55386302

Email [email protected]

Skills and Experience

1
Management

1. In house executive management training, over ten years, with emphasis on

interpersonal communication, both inter and intra cultural. Understanding of ISO and
TQM, which includes change management.

2. Budget control, analysis and financial modelling in the acquisition and development of new
business. General aspects of operational, control and supply management.

3. Understanding of government structures and dealing with bureaucrats and politicians,

especially in India, in general and in regards to R&D and government funding.

4. Development of strategic alliance and joint venture agreements through a memorandum of

understanding and heads of agreement to final contract and tenders.

5. Negotiation skills to achieve a win-win situation against different cultural and political
backgrounds.

Marketing

1. Statistical analysis and surveys relative to product positioning and competition.

2. Development of sales strategy and tactics based on (1) and product evaluation with
respect to the Therapeutic Goods Advertising Code and National Co-ordinating
Committee on Therapeutic Goods.

3. Product presentation and information detailing for the end user, sales personnel and
distributors. Product launches promotion and advertising.

4. Sourcing appropriate distributors with regards to their corporate structure, finance and
technical knowledge. Establishing agreed criteria to monitor the distributors
performance.

5 Identifying market needs and developing strategies for market penetration.

6 Developing corporate relationships (push/pull) within the marketing strategy.

7 Developing, branding, and or maintaining the Corporate image and philosophy.

2
Business Development

1. Identification of potential new business / products through think tank sessions, opportunity and
analysis of market requirements.

2 Identifying intellectual property, acquisition and patenting relative to the commercial

environment.

3 Development of business plans for the acquisition of business / products and financial and
socioeconomic modelling, with respect to maintaining financial viability.

4 Consideration of supply and operational management of the business and marketing.

5 Development of preliminary patent applications.

6 New business developed in excess of 60 million Australian Dollars; business

portfolio 500 million Australian Dollars.

Biomedical

1 The statistical design, monitoring and analysis of clinical trials in accordance with the
T.G.A guidelines for good clinical practice.

2. Laboratory evaluation of drugs / natural compounds, including toxicology and

bioavailability prior to stage 1, 2 and 3 clinical trials.

3. The use of product evaluation and clinical trial data for patent application.

4 Areas of scientific specialisation : Immunology, Oncology and Human Reproduction.

5 Area of technical experience : carbohydrate and protein biochemistry and immuno-

diagnostic tests.

6 Industrial experience : Fermentation technology, protein and secondary metabolite production,

scale up to pilot production.

7 The design and delivery of health / awareness education programmes to the lay
public.

3
 8 Qualifications: B.Sc.Hon. M.Sc. Phd. ( UK ) Biology and Biomedical Sciences. Further training
in the USA with the WHO.

Employment History
2006 - Self employed BMC and private Tutor in health sciences problem solving, academic writing
and research methods

1999- 05
Karnataka State Government.
We have been working with the Queensland State Government to establish trade and
technology transfers Private consultant working for Mobius International Pty. Ltd.on contract as
director of corporate affairs. The company represents finance houses in North America and formed a
consortium with Ryder Hampton Pty. Ltd.(International Concept Designers), Bligh Voller Pty. Ltd.
(International Architecture Group), Brown and Root Pty. Ltd.(International Planning and Engineering
Group) and Ryder Hunt Pty. Ltd.(International Quantity Survey and Project Management Group). My
main responsibility is to represent the company and negotiate on their behalf with the Karnataka State
Government of India, for the development of infrastructure, tourism and hospitality. This involves
investment in toll roads, waste management, new building technologies, hotels, theme parks, zoo /
safari park and multi-level tourism. In addition we are negotiating for the first gambling / casino
licence in India. The total portfolio is in excess of 500 million Aust. Dollars and the first phase is at
the stage of contractual between Queensland and Karnataka, with the aim of developing sister
statehood. The M of U to this effect has been signed.

1997-1999
Position: Director Marketing. Company Seri Pardam Pondicherry-India.
Medium size company 50 staff. As director of marketing I was responsible for the development of
new natural-medicinal products; skin care and hygiene products and market strategies for product
branding and market positioning. Design of clinical trials,
monitoring and analysis. Product launches and development of media relations for product press
releases. Training and working with the sales team and establishing sales targets and incentives.
Introduction of total quality management practice (TQM ). I also advised local companies on
biotechnology development and regional banks on product marketing and corporate image
development. While in Pondicherry I was approached by the Territory Government for advice on
tourism and hospitality development, and successfully obtained the interest of an Australian company
(Mobius). Through this involvement in tourism and hospitality I gained experience in dealing with
Indian State Governments and the Central Government and their administrative systems. (The interests
of Mobius was transferred to Karnataka)

1995-1997
Position: International Marketing Manager. Company Main Camp Pty. Ltd.
.An investment R&D company. The company banking and treasury was based in Hong Kong.
Investment agents and underwriters were based in Perth. Head Office for Prospectus development was
based in Sydney. Marketing was based in Ballina with the initial priority to develop the market for tea
tree oil. I worked in all sections of the company. My initial main responsibility was Development of a
world wide distribution net work for tea tree oil. The presentation of seminars, at trade shows, on the

4
science-technology and use of tea tree oil. Similar presentations to the marketing, R&D and
purchasing departments of companies world wide. Demonstration of product value adding by the use
of tea tree oil and potential market demand by market surveys and statistical analysis. Design of trade
show stands and presentation, design of brochures, literature, and publication of articles in trade
journals.
Development of new business by the acquisition of potential new natural and pharmaceutical
products from university research, or any idea or product that had commercial potential. Market
analysis and prospectus development for potential investors and presentation at investors meetings
followed by project reports. Business developed was in excess of sixty-million Aust. Dollars.

1995
Position: Senior Lecture. Company: University of Queensland. Department of
Obstetrics and Gynaecology.
Service
1. Committee member on Faculty for computers and B.Med. Sci. candidates.
2. Chairman for Animal Ethics Committee.
3. Assessment of grant applications, external and internal.
4. Examiner for Royal College of Obstetrics and Gynaecology (science)
5. Tertiary course design in science, human reproduction and oncology.
6. Lay education cancer and its treatment.
7. Member of International Conference Committee and Chairman in human reproduction.
8. Development of research team including postgraduate and project students.

Awards and Fellowships

1. Biological Society Lecture Prize (U.K)

2. Tate and Lyle MSc. Scholarship (U.K.)
3. World Health Organisation Research Grant (U.S.A)
4. World Health Organisation Phd. Scholarship (U.K)
5. World Health Organisation Work Group (France)
6. University of Queensland Fellowship
Research Support
WHO, NH&MRC, Queensland Cancer Fund, Population Council of New York (USA),
Wenkart Foundation and The Australian Tobacco Foundation
Supervision of Research Students and Research Staff
8 Phd, 2 BMSc, 1 MSc, 40 Project Students and 5 Research Staff

5
Publications
100 scientific articles, which includes reviews, chapters in textbooks and patents.

Teaching Assessment

6
Topics : Human Reproduction and Oncology

Grades : 1(strongly agree), 2(agree), 3(uncertain), 4(disagree), 5(strongly disagree)

MEANS
Cum.Uni. : Dr. B Daunter
(1) Sessions were organised to ensure maximum learning. 2.3 1.6
(2) The objectives for each session were clear. 2.3 1.6
(3) The lecturer’s explanations were clear. 2.2 1.6
(4) The lecturer seemed well prepared for session. 1.8 1.1
(5) The lecturer stimulated my interest in the subject. 2.6 1.4
(6) The lecturer seemed willing to offer individual help. 2.1 1.4
(7) The lecturer made assessment requirements clear. 2.1 NA
(8) There were enough opportunities to ask questions. 2.1 1.1
(9) motivated me to work hard. 2.9 2.0

Grades : 1(good), 2(fair), 3(don’t know), 4(poor), 5(very poor), NA(not applicable)
(10) How would you rate this subject . 4.7 2.1
University Distribution
Outstanding Very Poor
Grades 1 2 3 4 5 6 7
Distribution % 2 4 9 25 33 24 3

(11) All things considered how would you rate this staff members overall effectiveness as a university
teacher. 5.1 2.0
University Distribution
Outstanding Very Poor
Grades 1 2 3 4 5 6 7
Distribution % 1 2 6 17 30 36 8

7
 Managerial Assessment
Australian Institute of Management

Supervisory Skill Assessment

RESULTS RATING
Task Team Individual Excellent Above Average
46 39 49 35-50 25-34

Leading - Planning Team Work 13-15 9-12

13 14 11

Decision Oral Written

Making Communication Communication
13 12 13 13-15 9-12

Goal Training Feed Back

Setting 13 15 13-15 9-12
15 13-15 9-12

Discipline
15 13-15 9-12

THOMAS KILMAN CONFLICT MODE ANALYSIS

RANK ORDER

COMPETING
COLLABORATING
COMPROMISE
ACCOMMODATING
AVOIDING

INTERPERSONAL COMMUNICATION

SCORE 120 : RATING DISTRIBUTION 90.73 + / - 19.5

LEADERSHIP BEHAVIOUR
Flexi-leader, depends on the situation and need, may involve authoritarian, participative and laissez-a-
fair leadership.
COUNSELLING STYLE
Basically a probing response, but depends on the situation and may involve evaluation, interpretation,
probing, understanding and supportive response.

8
 General Leadership and Managerial Philosophy
TQM is not a formula that can be applied to resolve a managerial problem. TQM draws our
attention to the fact that a corporate structure is a macro-ecosystem made up of interacting micro-
ecosystems. The interacting micro-ecosystems have to be integrated if the macro-ecosystem is to
evolve. In order to achieve this an appreciation that function, to a large extent, determines structure;
and that function is the collective efforts of the stakeholders. In this respect, it is necessary to
appreciate that different stakeholders will use different pathways to achieve the same function, this is
fuzzy logic, the way we think. Therefore the structure will take on a degree of fuzzy logic, which in
essence represents the individuals in the functional-structure; as opposed to a limited representation or
non-representation in a structured-function. Whereas the structured-function allows for few new ideas,
the functional-structure allows for natural selection to operate on the variables, new ideas and variants,
within the limits of the ecosystem. This allows for a collective functional vision and mission to be
developed by the stakeholders.
The overall picture of the collective functional vision and mission, must be understood by the CEO.
The CEO then works with the stakeholders to ‘paint in the details’. The CEO must do reality checks
to see if the vision and mission is achievable and has not become a mirage, and report such findings to
the stakeholders. In this way adjustments to the strategy and tactics can be made to achieve the
objective. This requires greater participation, in a functional-structure, by the stakeholders in obtaining
training and experience for the discharge of their increased responsibilities and accountability. This
can be achieved through the system of unit rotational portfolio allocation. In this way the unit
portfolios make up the appropriate portfolio of the executive. This promotes communication between
the portfolio holders and the integration of the unit portfolios into the executive overall picture, which
allows for effective operational / line management.
These general considerations are apart of the functional-structure culture-image that creates
confidence in the market place, corporate integrity. Corporate integrity is the ship that marketing
strategy and tactics can sink if they do not accurately reflect the product in a ‘true light’. The product
must meet the needs and expectations of the local, national and international markets, which may be
different. This can be achieved through adaptation in a functional-structure that will avoid conflicts in
the market place. This is important since markets are more decreeing in the user pay society, and
demand quality. Quality starts with accepting that the markets are stakeholders, and not ‘fodder’ to
drive the corporate machine.

9
 HOBBIES AND INTERESTS
1. Regular health and fitness programme at gymnasium.
2. Music in general and playing classical guitar.
3. Sailing, seamanship and navigation.
4. Writing novels and poetry.

REFEREES
(1) Colleague. Commercial
Mr. Bede Hampton Chairman Mobius International Pty. Ltd.
124 Enoggara Terrace Paddington
Brisbane. Qld. 4064
Phone (07) 3369 9888
Fax. (07) 3367 009
E-mail [email protected]

(2) Hon Mike Ahern (Past Premier of Queensland)

Special Commissioner of Trade (Africa Middle East and Sub-Continent)
Representing the Premier of Queensland.
111, George Street Floor 21
Brisbane Qld. 4000 PO Box 168 Albert Street Brisbane Qld. 4002
Phone (07) 3224 5365
Mobile 407 172 312
Fax (07) 3234 1527
E-mail [email protected]

(3) Colleague. Head of Department

Professor of Obstetrics & Gynaecology J. Morrison (Arab Emirates. Retired).
55-59 Coast Road
Macleay Island
Qld. 4184
Phone. 07 3409 5230

(4) Colleague in private consultancy.

Dr. G. Morris.
The Woodlands,
Fair Oaks.
Slitting Mill.
Rugeley. Staffs. WS15 2UU
UK
Phone. 44 18 8958 4775
E-mail [email protected]

10
 Publications
Dr. Brian Daunter

1 Greenshields RN, Morris GG, Daunter B, Alagaratnam R, Imrie FKE. The production of
fungal biomass in aerobic tower fermenters. First International Mycological Congress.
Great Britain, Seotember 1971.

2 Greenshields RN, Alagaratnam R, Coote SDJ, Daunter B, Morris GG. Growth and
morphology of microorganisms in tower fermenters. Proceedings IVth International
Fermentation symposium Japan, March 1972.

3 Daunter B, Gceenshields RN. Toxicity of Cladosporium cladosporides. J Gen Microbiol

1973J5:sv.

4 Elstein M, Daunter B. Trace elements in cervical mucus. In: Cervical Mucus in Human
Reproduction. WHO Colloquium, September 1973 (Eds Elstein M, Mognissi K), Publ
Scriptor, Copenhagen 1973;Chapter 10.129-127.

5 DaunterB, Elstein. M. Serum levels of cooper, caeruloplasmin and caeruloplasmin oxidase

activity in women using copper-containing intrauterine devices and in women taking
combined oral contraceptives. J Obstet Gynaecol Br Cwlth 1973; 8C):644-647.

6 Elstein M, Daunter B. Scanning Electronmicroscopy of human cervical mucus in the

normal menstrual cycle. Proceedings IVth International Meeting of Polish Obstetricians
and Gynaecologists on the Cervical Factor Bialoweiza, Poland, June 1975.

7 Daunter B, Chantler EN, Elstein M. The scanning electron microscopy of human

cervical mucus in the non pregnant and pregnant states. Eur J Obstet Gynaecol
1976; 83(g):738 74-3.

8 Elstein M, Daunter B. The structure of cervical mucus. In: The Cervix (Eds Singer A
Jordan JA), Publ WE Saunders Co Ltd, London 1976;Chapter 11:137-146.

9 Elstein M, Daunter B. The electron microscopy of human cervical mucus in the normal
menstrual cycle and the first trimester of pregnancy. In: The Uterine Cervix in
Reproduction (Eds Inster V, Bettendort G) 197-7;pp.52-62.

10 Daunter B. Sialic acid levels and scanning electronmicroscopy of cervical mucus.

Contraceotion 1978; 17(1,1):27-34.

11 Daunter B, Chantler EN, Elstein M. Trace metals (Cu, Mn, Zn, Fe), sulphydryl and
disuilphide groups of cerical mucus. Contraception 1977;15(5):543-552

12 Daunter B, Chander EN, Elistein M. The effect of a low dose progestogen on the trace
metal content and disulphide and sulphydryl groups in cervical mucus. Contraception
1978; 117(l):35-40.

13 Daunter B. Sialic acid levels and scanning electron microscopy of cervical mucus.

11
Digest Ob/Gyn 1979;pp.120-121.

14 Hill R, Daunter B, Khoo SK Mackay EV. Isolation of tumour- associated

immunaglobulins from ascitc fluid. Br J Cancer 1978,38(l): 154-157.

15 Khoo SK Daunter B, Mackay EV. Carcinoernbryanic antigen and beta-microglobulin

as serum tumour markers in women with genital cancer. Int J Gynecol Obstet
1979; 16(5): 388-393.

16 Khoo SK Mackay EV, Daunter B. dinitrochlorobenzene reactivity of women with

cancer of the ovary, cervix and corpus uteri. Int J Gynaecal Obstet 1979; 17 (1) 58 – 62

17 DaunterB, Khoo SK Mackay E/. Lymphocyte response to plant mitogens. I. The

distribution of lymphocyte response to various doses of phytohaemagglutinin-M in
pregnant women and women with carcinoma of the cervix or the ovary.
Gynecol Oncol 1979; 7(3): 309-313.

18 Daunter B, Khoo SK, Mackay EV. Lymphocyte response to plant mitogens. II. The
response of lymphocytes from women with carcinoma of the Cervix to phytahemagglutinin
P, concanavalin A and pokeweed. Gynecoi Oncol 1979; 7 (3): 314-317.

19 Daunter B, Khoo SK Mackay EV. I Lymphocyte response to plant mitogens.

Gynecol Oncol 1979.,8(2):198-203.

20 Daunter B. A new concept of contraception. Impulse 1979; 17(17):1 &5.

21 Daunter 3. New type of pill. Scientffic Australian Jan 1979:3(l): 11-13.

22 Daunter 9Mackay EV. The reversal immune surveillance hypothesis. Med Hypotheses
1979; 5(11):1207-1299.

23 Dunter B.Cervical mucus in reproduction. Proceedines IVth International Symposium

on Glycoconjugates Kiel, Fed Republ Germany, September 1979
(Eds Schauer B, Boer R, Buddecke F et al) Publ Georg Thieme, Stuttgart pp. 550-552.

24 Daunter B,Hill AR. Antigenic antics of glycoproteins in ovarian cancer.

Proceedings IVth international Svmposium on GIycoconjugates Kiel, Fed Republ
Germany, September 1979 (Eds Schauer B. Boer R, Buddecke E etal), Publ Georg
Thieme, Stuttgart pp 641- 642.

25 Khoo SK Daunter B. The beta-subunit of chorionic gonadotrophin as a tumour marker

in gestational trophoblastic disease. Aust NZ J Obstet Gvnaecol 1980; 20(1):35-42.

26 Daunter B,Counsilman C. Cervical mucus: its structure and possible biological

Functions. Eur. J Obstet Gynaecol Reprod Biol 1980; 10(3):141-161.

27 Sariadi S,Daunter B, Mackay E, Magon H, Koo SK. A multiparametric approach to

tumour markers detectable in serum in patients with carcinoma of the ovary or uterine
cervix. Gynecol Oncol 1980;10(2):113-124.

12
28 MackayEV, Koo SK Daunter B. Tumour Markers. In: Gynecologic Oncology.
Fundamental Principles and Clinical Practice (Ed Coppleson M),Churchill-Livingstone,
Edinburgh 1981;Vot 1, Chapter 21:pp.270-282.

29 DaunterB, Mackay EV. The reversal immune surveillance hypothesis: part II. Med
Hypotheses 1981; 7(5): 555-590.

30 Daunter B,Hill R, Hennessey J, Mackay EV. Seminal plasma biochemistry. I

Preliminary report:a possible mechanism for the liquefaction of human seminal plasma
and its relationship to spermatozoal motility. Androiogia 1981,13(2): 131-141.

31 Daunter E, Newlands J. Seminal plasma biochemistry. II. Seminal plasma and

spermatozoa]cytidine monophosphate-sialic acid synthetase and siatyttransferase activities.
Andrologia 1981,13(3): 215-224.

32 Daunter B.Infertility: cervical mucus and semen factors. Eur J Obstet Gynaecol Recrod
Biol 1981; 12(4):247-256.

32 Daunter B, Silburn P, Hill R. Mobius DNA, the paper tiger. Med Hypotheses
1981; 7(3): 285-310.

34 Magon H, Daunter B, Koo SK Mackay EV. A comparison of two radioimmunoassay

methods for the detection of carcinoembryonic antigen in patients with ovarian or cervical
cancer. Gynecol Oncol 1981; 11(3):340-347.

35 Hill R, Daunter B, Koo SK Mackay EV. Nature of carcinoembryonic antigen purified

from malignant ascitic fluid of serous cystadenocarcinoma of the ovary. Mol Immunol
1981; 18(7): 647-653.

36 Hill R, Daunter B, Magon H, Khoo SK Mackay etel. A comparison of the

physicochemical properties of carcincoembryonic antigen in extracts of tumour tissue,
ascitic and cyst fluid from ovarian cancer. Aust J Ext) Biol Med Sci 1981; 59(4):469-476.

37 Khoo,SK Hill R, Daunter B, Mackay EV. Carcinoembryonic antigen in ovarian cancer:

correlation of concentrations in tumour tissue, cyst fluid, ascitic fluid and peripheral blood.
Aust NZ J Obstet Gvnaecol 1982. 22(2): 65-70.

38 Daunter B, Khoo SK, Mackay EV. Monocyte chemotaxis in patients with cervical or
ovarian cancer. Gynecol Oncol 1982;13(2):152-157.

39 Daunter B, Lutjen P. Cervical mucus: In: Atlas of Human Reproduction by Scanning

Electron Microscoov. (Eds Hafez ESE, Kenemans P), Publ MITP Press Ltd.,
1982;Chapter 7:p.55.

40 Daunter B, Cole K, Mackay EV, Khoo SK The effects of smoking on the immune
response in term pregnancy. Indian J Chest Dis Allied Sciences (Suppl on Saioking)
1982; pp. 171-186.

13
41 Hill R, Khoo SK, Daunter B, Silburn PA, Mackay EV. Immunoglobulins reactive to
carcinoembryonic antigen and their relationship to the antigen in malignant ascitic fluid of
ovarian carcinoma. Int J Cancer 1982; 30(5):587-592.

42 Silburn PA, Koo SK, Daunter B, Hill R Roberts TK, Mackay EV. Types of immune
complexes in the ascitic fluid of women with carcinoma of the ovary. Int Arch Allergry
Immunol 1983;71(3):219-923.

43 Hill R, Daunter B, Silburn PA, Khoo SK, Mackay EV. Affinity chromatography
separation of tumour associated antigens from ascitic fluid of ovarian cancer patients.
Gynecol Oncol 1983; 1 5(3):428- 433.

44 Poiak B, Daunter B. Scanning electron microscopy and histological examination of

human seminal plasma coagulum. Androlocia 1983;15 (5):452- 462.

45 Daunter B,Mackay EV. Occasional review. Histocompatibility antigens. Aust NZ J

Obstet Gynaecol 1984; 23 (4):231-236.

46 Silburn PA, Koo SK Daunter B, Hill R, Mackay etel. Immune complexes in ovarian
cancer: association between IgM class complexes and antinuclear autoantibodies in
ascitic fluid. Int Arch Allergy Appl Immunol 1984; 74:63-66.

47 Sillburn PA, Khoo SK, Daunter B, Hill R, Mackay EV. Demonstration of tumour
associated immunoglobulin G isolated from immune complexes in ascitic fluid of ovarian
cancer. Diagnostic Immunol 1984;2: 30-35.

48 Daunter B.Review: Biochemical functional-structural aspects of human cervical mucus.

J Scan Electron Microscopy 1984; 1:343-358.

49 Daunter B, Khoo SK. A review. Role of cervical mucus in human infertility. Aust NZ J
Obstet Gvnaecol 1984,24:271-275.

50 Polak B, Daunter B. Osmolarity of human seminal plasma. Andrologia1984;

16(3): 224-227.

51 Daunter B. RISH III. Haptotype-sharing in immune responses. Invited article.

Med Hypotheses 1985; 17 (2):79-93.

52 Daunter B. RISH IV. Antibody divesity. Invited article. Med Hypotheses

1985; 17(3): 197-218.

53 Daunter B. RISH V. Application to human monoclonal antibody production.

Invited article. Med Hypotheses 1985; 17 :337-353.

54 Daunter B. Monoclonal antibody production and RISH. Invited article.

Indust Biotechnol 1985.

14
55 Maynard K, Musk P, Daunter B, Khoo SK, Parsons PG. Melphalan resistant
lymphoblastoid cell lines, established from patients with ovarian cancer, treated with
crosslinking agents. Aust J Exp Biol Med Sci 1985; 63(3): 333-341.
56 Daunter B. Packing of spheres in embryogenesis and carcinogenesis. Med Hypotheses
1986; 21:61-70.

57 Daunter B. Jaa-Kwee D, Mikiosi S, Wright G. Ovarian tumour antigens. Preliminary

histological investigations. Gynecol Oncol 1986; 23: 364-370.

58 Polak B, Daunter B. N-acetylneuraminic acid and hostile.mucus infertility.

Europ J Obstet Gynaecol Reprod Biol 1987; 26: 57-68.

59 Shield PW, Daunter B, Wright G. An overview. The Pap smear revisited.

Aust NZ J Obstet Gynaecol 1987; 27(4):269-282.

60 Daunter B. RISH VI. General evolutionary aspects of the immune system.

Med Hypotheses 1988; 27: 115-126.

61 Daunter B. RISH VII. Cell surface patterns – association of like cells.

Med Hypotheses 1988; 27: 127-132.

62 Daunter B, Shield PW. The Pap smear is alive and well. J Mod Med 1989;March: 14-23.

63 Poialk B, Daunter B. Seminal plasma biochemistry. IV. Enzymes involved in the

coagulation and liquefaction of human seminal plasma. Int J Andrology 1989; 12:187-194.

64 Cham BE, Daunter B. Curaderm (antineoplastic). Drug News and Perspectives

1989; 2: 112.

65 Daunter B. Australian Patent 588807 Vaginal Contraceptive 1989.

66 Daunter B. USA Patent 4,959,216 Vaginal Contraceptive 1990.

67 Daunter B, Shield PW. Pap smear is alive and well. Scand J Mod Med
1990; 1 (5):137-144.

68 Mackay EV, Khoo SK, Daunter B. Tumour Markers In: Gynecologic Oncology.
Fundamental Principles in Clinical Practice (Ed Coppleson M)
Publ Churchill-livingstone Edinburgh 1990. Voi 1 Chap 2.

69 Polak B, Daunter B. Seminal plasma biochemistry. III. Characterization of coagulum

components. Eur J Obstet Gynaecol Reprod Biol 1990; 223-234.

70 Daunter B. Tumour Markers in Gynecologic Oncology (Review). In:Gynecologic

Oncology 1990; 1-15.

71Cham BE, Daunter B. Topical treatment of premalignant and malignant skin cancers
with Curaderm. Drugs of Today 1990; 26:55-58.

15
 72 Cham BE, Daunter B, Evans R. Curaderm. Aust J Med 1990; 152:329-330.

73 Daunter B, ChamBE. Solasodien glycosides: In vitro preferential cytotoxicity and mode

of action for human cancer cells. Cancer Letters 1990; 209-220.

74 Cham BE, Daunter B. Solasodine glycosides. Inhibition of cytotoxicity by rhamnose in

mice with sarcoma 180. Cancer Letters, 1990; 221-225.

75 Cham BE, Daunter B, Evans RA. Topical treatment of malignant and premalignant skin
lesions by very low concentrations of a standard mixture of (BEC) of solasodine glycosides.
Cancer Lett. 1991 59 (3) 183 - 92

76 Daunter B. RISH The basic arguments. Med Hypotheses 1991

77 Daunter B. Immune response self-foreignness. Med. Hypotheses 1991 36 (1) 75 – 89

78 Shield PW, Wright RG, Free K, Daunter B. The accuracy of cervicovaginal cytology
in the detection of recurrent cervical carcinoma following radiotherapy. Gynecol Oncol.
1991 41(3) 223 – 9

79 Daunter B. European Patent 85901921.8 Vaginal Contraception 1991.

80 Shield PW, Wright RG, Daunter B. Post-irradiation cytology of cervical cancer patients.
Cytopathology 1992 3 (3) 167 – 82

81 Daunter B Immune response tissue specific T – lymphocytes. Med Hypotheses

1992 37 (2) 76 – 84

82 Daunter B. Immunology of pregnancy : towards a unifying hypothesis.

Eur. J Obstet Gynecol Reprod Biol. 1992 43 (2) 81 – 95

83 Daunter B, Forbes KL, Sanderson BM, Morrison J, Wright RG. Inhibition of binding
of bacteria to amniochorionic membranes by amniotic fluid.
Eur J Obset Gynecol Reprod Biol 1992 47 (2) 95 – 102

Book Reviews

1 Meternofetal Transmission of Immunoglobulins. Ed. A. A. Hemmings. Cambridge

University Press. Review Publ. ANZJ Obstet. Gynaec. (1977)

2 Immunology of Gametes. Eds. M. Adidin and M. H. Johnsen. Publ. Cambridge

University Press. Review Publ. ANZJ Obstet. Gynaec. (1977)

3 Fertilization Mechanisms in Man and Mammals. Ed. R. B. Gwatkin. Pulb. Plenum

Press. New York / London. Review Publ. Australian Med. J. (1978)

16
17